Key result
TGF-β plasma concentrations were independently associated with the occurrence of hepatic steatosis in overweight adolescents, serving as a potential biomarker for steatosis risk.
Why the study?
Routine biochemical non-invasive tests have low accuracy for diagnosing nonalcoholic fatty liver disease in childhood.
Are TGF-β plasma levels associated with hepatic steatosis in overweight pediatric patients?
Cross-Sectional (n=72)
Are TGF-β plasma levels associated with hepatic steatosis in overweight pediatric patients?
TGF-β may serve as an important non-invasive biomarker to evaluate the risk of hepatic steatosis development in overweight adolescents.
TGF-β association with HS in overweight adolescents is hypothesis-generating; prospective validation required before any diagnostic role.
Nonalcoholic Fatty Liver Disease (NAFLD) is a common cause of chronic liver disease in childhood and strongly associated with obesity. Routine biochemical non-invasive tests remain with low accuracy for diagnosis of NAFLD. We performed a cross-sectional study to examine potential associations between anthropometric and biochemical parameters, specially TGF-β, a prognosis marker for hepatic steatosis (HS). Between May and October 2019, seventy-two overweight adolescents were enrolled, of which 36 had hepatic steatosis. Hepatic, lipidic and glycemic profiles, and levels of vitamin D, ferritin and TGF-β were analyzed. Hierarchical cluster and a discriminant model using canonical correlations were employed to depict the overall expression profile of biochemical markers and the biochemical degree of perturbation. Median values of alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), and TGF-β were higher in the adolescents with HS. Values of body mass index (BMI)/age and ALT, but not of TGF-β, were gradually increased proportionally to augmentation of steatosis severity. In a multivariate analysis, TGF-β plasma concentrations were associated with occurrence of hepatic steatosis independent of other covariates. Discriminant analysis confirmed that TGF-β concentrations can identify HS cases. Our data reveal that HS patients exhibit a distinct biosignature of biochemical parameters and imply TGF-β as an important biomarker to evaluate risk of steatosis development.
No takes yet. Share an insight, caveat, or question.
Barretto et al. (2020) conducted a cross-sectional in Hepatic steatosis (n=72). Hepatic steatosis vs. Overweight adolescents without hepatic steatosis was evaluated on Association between TGF-β plasma concentrations and occurrence of hepatic steatosis. TGF-β plasma concentrations were independently associated with the occurrence of hepatic steatosis in overweight adolescents, serving as a potential biomarker for steatosis risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: